{"id":164417,"date":"2022-12-24T00:13:09","date_gmt":"2022-12-24T05:13:09","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/valneva-completes-bla-submission-to-u-s-fda-for-its-single-shot-chikungunya-vaccine-candidate\/"},"modified":"2024-08-18T11:44:56","modified_gmt":"2024-08-18T15:44:56","slug":"valneva-completes-bla-submission-to-u-s-fda-for-its-single-shot-chikungunya-vaccine-candidate","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/valneva-completes-bla-submission-to-u-s-fda-for-its-single-shot-chikungunya-vaccine-candidate.php","title":{"rendered":"Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate"},"content":{"rendered":"<p><![CDATA[Saint-Herblain (France), December 23, 2022 \u2013 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that it has completed rolling submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its single-shot chikungunya vaccine candidate, VLA1553. Valneva is seeking approval of its investigational chikungunya vaccine in persons aged 18 years and above.]]><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2022\/12\/23\/2578972\/0\/en\/Valneva-Completes-BLA-Submission-to-U-S-FDA-for-its-Single-Shot-Chikungunya-Vaccine-Candidate.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate\">Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more: Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/valneva-completes-bla-submission-to-u-s-fda-for-its-single-shot-chikungunya-vaccine-candidate.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-164417","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164417"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=164417"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/164417\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=164417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=164417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=164417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}